Rationale: TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) is well reported as an inducer of apoptosis in tumor models; however, its role and function in vivo in atherosclerosis and vascular injury has not been established. Objective: We sought to study the function of TRAIL in cardiovascular pathology and its regulation in vivo. Methods and Results: Here, we show that TRAIL was upregulated in medial vascular smooth muscle cells (VSMCs) 24 hours following perivascular cuff placement around femoral arteries of mice. We also show that TRAIL mRNA and promoter activity was induced in VSMCs following in vitro mechanical injury. Intimal thickening 15 days after cuff placement was reduced 2-to 3-fold in TRAIL ؊/؊ compared to wild-type mice and was reversible by administration of recombinant TRAIL. Additionally, reduced VSMC proliferation was observed in injured arteries of TRAIL ؊/؊ mice. Fibroblast growth factor (FGF)-2, a potent growth factor released following vascular injury, was also reduced in arteries of TRAIL ؊/؊ mice, and VSMCs isolated from these animals did not respond to FGF-2 in vitro. Injury and FGF-2 regulated TRAIL transcriptional activity via 2 specificity protein (Sp)1 elements in the proximal TRAIL promoter, a binding site also shared by nuclear factor (NF)B. Mutational studies confirmed a role for Sp1 in injury-and FGF-2-inducible TRAIL transcription. Furthermore, increased NFB expression after injury transactivated the TRAIL promoter. Interestingly, following mechanical injury, Sp1 phosphorylation (Thr453) and an increase in the physical interaction of p-Sp1(Thr453) with NFB was observed. Conclusions: We conclude that TRAIL induction involves FGF-2, Sp1-phosphorylation and NFB and that TRAIL promotes VSMC proliferation and neointima formation after arterial injury. (Circ Res. 2010;106: 1061-1071.)
T RAIL (tumor necrosis factor-related apoptosis inducing ligand) is expressed by a variety of cells, traditionally known to induce apoptosis via the death receptor pathway analogous to Fas ligand (FasL). Unlike FasL, however, TRAIL apoptotic signaling occurs following its engagement with 2 death domain-containing receptors, death receptors 4 and 5 (DR4 and DR5). Additional receptors are also present in humans, including decoy receptors 1 and 2 (DCR1 and DCR2) and osteoprotegerin, which may compete with DR4 and/or DR5 for TRAIL binding, thereby protecting cells from apoptosis. 1, 2 TRAIL expression is regulated by insulin, interferons type I and II, and transcription factors Stat1, nuclear factor (NF)B, Egr2/3 (early growth response factor 2/3), and IRF-1/3/7 (interferon regulatory factor 1/3/7). 3 In the vessel wall, TRAIL is expressed in vascular smooth muscle cells (VSMCs), endothelial cells (ECs), macrophages, and T cells (reviewed 3 ); however, the role and regulation of TRAIL in cardiovascular disorders is currently controversial. Under certain conditions TRAIL can induce apoptosis of vascular cells which may contribute to apoptosis within the vessel. 4 -6 TRAIL can also stimulate proliferation and migration of ECs and fibroblasts in vitro. [7] [8] [9] Recently, we showed that failed aortocoronary saphenous vein bypass grafts express TRAIL in VSMCs, colocalizing to regions of cell proliferation and increased expression of insulin-like growth factor receptor-1 (IGF1R), a potent antiapoptotic growth factor receptor for VSMCs. 10 We also demonstrated that TRAIL plays a prosurvival and proproliferative role in VSMCs via the induction of IGF1R expression by NFB. The proliferative effect of TRAIL in VSMCs was via its interaction with receptors DR4 and DcR1. 10 The role and function of TRAIL is therefore more complicated than originally foreseen.
To study the function of TRAIL in cardiovascular pathology and its regulation in vivo we performed cuffinduced injury to the femoral arteries of TRAIL Ϫ/Ϫ and wild-type (WT) mice, which results in neointimal lesions similar to those observed in humans. 11, 12 Here, we report, for the first time, direct evidence that TRAIL signaling plays an important role in neointima formation after arterial injury in vivo. Growth factors such as fibroblast growth factor (FGF)-2 mediate neointima formation 13 and we show that injury and FGF-2 regulate the expression of TRAIL, transactivated by specificity protein (Sp)1 and NFB. Representative cross section (ϫ60). Positive staining was quantified using ScanScope as described in Methods (nϭ4). C, TRAIL protein expression was increased in both media and lysate of human VSMC cells 24 hours after scraping injury, as determined by TRAIL ELISA (R&D Systems). D, TRAIL mRNA expression after mechanical injury in pup rat VSMC, as determined by real-time PCR 24 hours after scraping injury (nϭ4). Values were normalized to ␤-actin. E, Injury activates the human TRAIL promoter. Pup rat VSMCs were transfected with pGL-1523Luc and assayed for luciferase activity 24 hours after scraping injury. Results are meansϮSE (nϭ3). These findings are representative of at least 2 independent determinations. *PϽ0.05. 
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Cell Culture
Human VSMCs were cultured in DMEM (Sigma) supplemented with 20% FCS. Rat aortic VSMCs and pup rat WKY12-22 VSMCs were cultured in Waymouth (Invitrogen) medium containing 10% FCS. Scraping injury was performed as previously described. 14
Transient Transfection and Luciferase Assays
VSMCs in 6-well-titer plate were serum-arrested for 24 hours before transfection of indicated constructs and 10 ng per well of the renilla reporter pRL-TK (Promega), at 60% to 70% confluence using FuGENE6 (Roche) for a further 24 hours. Luciferase activity was quantified using the Dual Luciferase Assay System (Promega) 16 to 24 hours later.
Femoral Artery Cuff Injury Model
Femoral artery cuff model was performed in WT and TRAIL Ϫ/Ϫ mice 15 as previously described. 16
Immunohistochemistry
Tissues were processed as previously described. 16, 17 
Statistics
Differences between groups were assessed with Student t test, one-way ANOVA and Mann-Whitney. Unless stated otherwise, all data are expressed as meanϮSEM. A value of PϽ0.05 was considered to indicate statistical significance.
Results
TRAIL Expression Is Induced by Vascular Injury
We have previously shown that TRAIL is expressed in failed saphenous vein bypass grafts in regions of proliferating VSMCs. 10 To determine whether vascular injury . BrdUrd-positive cells as a percentage of total cells found in the media and intima of WT and TRAIL Ϫ/Ϫ arteries (nϭ3). D, Representative active caspase-3 staining (ϫ100). Positive staining was quantified using ScanScope as described in Methods (nϭ3). E, Effect of TRAIL administration to WT and TRAIL Ϫ/Ϫ mice following cuff-induced injury. Human recombinant TRAIL (R&D Systems), or water vehicle, was injected daily by IP for 15 days following cuff placement. Arteries were stained with elastin/van Gieson, and intima/media ratio was determined as described in Methods. *PϽ0.05.
stimulates TRAIL expression, or if TRAIL regulates VSMC proliferation in vivo, we examined TRAIL expression in an arterial cuff injury model using WT C57BL/6 mice. Figure 1A demonstrates that TRAIL expression is increased in medial VSMCs (identified by smooth muscle ␣-actin staining) 24 hours after cuff placement of femoral arteries. Active caspase-3 expression was virtually undetectable with no change 24 hours after cuff placement between groups ( Figure 1B) . In contrast, a significant increase in proliferating-cell nuclear antigen (PCNA)positive VSMCs was observed within the media of WT injured arteries ( Figure 1B ). Following in vitro mechanical injury, 18 conditioned medium and lysates from VSMCs contained increased TRAIL as measured by ELISA ( Figure  1C ), and injured cells showed increased TRAIL mRNA ( Figure 1D ) and TRAIL transcriptional activity ( Figure  1E ). Taken together, these findings indicate that TRAIL promoter activity and expression is increased after VSMC injury both in vitro and in vivo.
Effect of TRAIL Deficiency on Intimal Thickening in Response to Cuff Placement
We have recently shown in vitro that TRAIL at low (0.1 to 10 ng/mL) concentrations, can increase VSMC proliferation within 24 hours, with the optimum concentration being 1 ng/mL, which does not induce VSMC apoptosis. 10 To determine whether TRAIL regulates VSMC proliferation in vivo, we examined the effects of cuff-induced arterial injury in TRAIL Ϫ/Ϫ and WT mice. Intimal thickening 15 days after cuff placement was reduced 2-to 3-fold in TRAIL Ϫ/Ϫ mice compared with WT ( Figure 2A ). No difference in medial area between TRAIL Ϫ/Ϫ and WT mice was observed (data not shown). However, VSMCs in injured arteries of TRAIL Ϫ/Ϫ mice showed reduced VSMC proliferation, demonstrated by 5-bromo-2-deoxyuridine (BrdUrd) incorporation, compared to WT mice ( Figure  2B ). A similar finding was also observed with PCNA (data not shown). In contrast, no change in apoptosis was observed between the 2 groups ( Figure 2C ). Administra- NI, neointima; L, lumen; A, adventitia. Positive nuclear FGF-2 staining was quantified using ScanScope as described in Methods (nϭ3). C, Proliferation of TRAIL Ϫ/Ϫ VSMCs is unaltered by FGF-2 (50 ng/mL). D, FGF-2 (50 ng/mL) activates the human TRAIL promoter. Pup rat VSMCs were transfected pGL-1523Luc for 24 hours before addition of agonists. Luciferase activity was assayed after 24 hours. Ang II indicates angiotensin II; EGF, epidermal growth factor; IL-1␤, interleukin-1␤; OPG, osteoprotegerin. E, FGF-2 activation of the human TRAIL promoter is dose-dependent. Pup rat VSMCs were transfected pGL-1523Luc for 24 hours before addition of FGF-2 at indicated concentrations (ng/mL) (nϭ3). Representative of at least 2 independent determinations. *PϽ0.05.
tion of 2 g TRAIL rescued intimal formation in TRAIL Ϫ/Ϫ mice, confirming that the reduced VSMC proliferation and neointima were attributable to lack of TRAIL ( Figure 2D ). There was no significant difference in plasma lipid levels, or markers of systemic inflammation between TRAIL Ϫ/Ϫ or WT mice, with or without injury (Online Figure I) . No change was observed in CD45positive and MAC3 numbers of cells within the neointima (Online Figure II) , nor was there any change in ECs (Online Figure II) . Taken together, these findings suggest that TRAIL alone can restore the neointima in TRAILdeficient animals and that TRAIL is an important regulator of VSMC proliferation following arterial injury.
Enhanced Expression of FGF-2 in Cuff-Induced Arterial Injury in WT Versus TRAIL ؊/؊ Mice
Vascular injury releases FGF-2, which promotes VSMC proliferation 14 and intimal hyperplasia. 13 TRAIL induced the expression of FGF-2 as determined by quantitative PCR ( Figure 3A ). We therefore examined whether reduced intimal thickening in cuff-injured TRAIL Ϫ/Ϫ mice, may be attributable to reduced FGF-2 expression following vascular injury. FGF-2 was expressed in WT mice following arterial injury at 15 days, predominantly in VSMC nuclei within the media and intima (indicated by arrows, Figure  3B ). In contrast, FGF-2 expression was reduced in injured arteries of TRAIL Ϫ/Ϫ mice ( Figure 3B ). Similar findings were also observed 4 and 24 hours after injury (data not shown). Furthermore, TRAIL Ϫ/Ϫ VSMCs did not respond to treatment of FGF-2 for 24 or 72 hours in vitro ( Figure  3C ), suggesting that TRAIL is required for the proliferative effect of FGF-2. We next wanted to determine whether FGF-2 regulates TRAIL transcription. VSMCs were transiently transfected with pGL-1523Luc for 24 hours and incubated with FGF-2 (50 ng/mL) for another 24 hours. FGF-2 activated the human TRAIL promoter, whereas interleukin-1␤, osteoprotegerin, epidermal growth factor, and angiotensin II had no effect ( Figure 3D ). Furthermore, FGF-2 induction of the TRAIL promoter was dose-dependent ( Figure 3E ). These findings suggest that FGF-2 regulates TRAIL transcription.
Injury and FGF-2-Inducible TRAIL Transcription Requires Sp1
Inspection of the proximal TRAIL promoter revealed 2 putative Sp1 binding elements (Sp1-1 and Sp1-2) ( Figure  4A ). To determine whether TRAIL is under the transcrip- Oligo-2, right sequence. B, Activity of the TRAIL promoter after transient transfection with Sp1. Serum-arrested (24 hours) pup rat VSMC were transfected with pGL-1523Luc and pcDNA3 Sp1 or pcDNA3 for 24 hours before determination of luciferase activity (nϭ3). C, Activity of the TRAIL promoter with transverse mutations to Sp1-1 (mSp1-1 pGL-1523Luc) and Sp1-2 (mSp1-2 pGL-1523Luc) binding sites following transfection with pcDNA3 Sp1 or pcDNA3 (nϭ3). D, Activity of the TRAIL promoter after injury and Sp1 inhibition. Dominant negative Sp1 (pEBG-Sp1) and its control (pebg-NLS) were cotransfected with pGL-1523Luc for 4 to 6 hours, before injury of cells by mechanical scraping. Twenty-four hours later, cells were harvested and luciferase activity determined (nϭ3). E, Activity of the TRAIL promoter after FGF-2 and Sp1 inhibition. Dominant negative Sp1 (pEBG-Sp1) and its control (pebg-NLS) were cotransfected with pGL-1523Luc for 24 hours, before FGF-2 addition for a further 24 hours. Cells were harvested, and luciferase activity was determined (nϭ3). Representative of at least 2 independent determinations. *PϽ0.05.
tional control of Sp1, transient transfection analysis was performed with pGL-1523Luc and luciferase activity determined. TRAIL promoter activity was induced by the Sp1 expression vector compared to its backbone control, pcDNA3 ( Figure 4B ). Transverse mutations in Sp1-1 and Sp1-2 generated in pGL-1523Luc abolished the ability of Sp1 to activate the TRAIL promoter ( Figure 4C ). Furthermore, injury-inducible TRAIL transcriptional activity was abrogated by the presence of a dominant-negative Sp1 mutant (pEBG-Sp1) ( Figure 4D ). FGF-2-induction of the TRAIL promoter was also blocked by pEBG-Sp1 ( Figure  4E ). These findings show that injury-and FGF-2-induced TRAIL transcription requires Sp1.
Sp1 Binds the TRAIL Promoter Following Injury to VSMCs
Electrophoretic mobility-shift assays (EMSAs) were performed to determine whether the putative Sp1 elements in the TRAIL promoter could support binding of Sp1. EMSA using recombinant Sp1 and double-stranded 32 P-labeled oligonucleotides spanning the region of Sp1-1 and Sp1-2 (Oligo-1 and Oligo-2) supported the formation of one main nucleoprotein complex ( Figure 5A, arrow) , that failed to form when the Sp1 motifs in Oligo-1 or Oligo-2 were mutated ( Figure 5A ). Nuclear extracts of injured VSMCs produced inducible nucleoprotein complexes with Oligo-1 and Oligo-2 ( Figure 5B ), which were supershifted with anti-Sp1 antibodies, but not with an irrelevant control antibody ( Figure  5B ), indicating that Sp1 occupies the synthetic TRAIL promoter fragments. Interestingly, binding of Sp1 to Sp1-1, but not Sp1-2, was abrogated with extracts isolated from injured VSMCs exposed to neutralizing FGF-2 antibody ( Figure 5C ). This suggests a role for FGF-2 and the interaction of Sp1 with Sp1-1 following injury, implicating additional mechanism(s) at play involving multiple nuclear factors at this site.
Sp1 Binding to the TRAIL Promoter Is Phosphorylated
Sp1 phosphorylation plays an important role in the regulation of many genes. 19 Sp1 phosphorylation was evident in basal and inducible nucleoprotein complexes (Oligo-1 and Oligo-2), because complex formation was abolished by prior incubation of the extracts with 5 U calf intestinal alkaline phosphatase (CIP) ( Figure 5B ). We have shown previously that FGF-2 stimulates extracellular signalregulated kinase 1/2-dependent phosphorylation of Sp1 on Thr453 and Thr739, which alters its interaction with the platelet-derived growth factor receptor ␣ promoter. 20 p-Sp1(Thr453) levels were also increased after mechanical injury of cultured VSMCs ( Figure 6A ), whereas no change in total Sp1 was observed ( Figure 6A ). Furthermore, p-Sp1(Thr453) injury-inducible levels were blocked with 10 mol/L FGF-receptor antagonist, SU5402 ( Figure 6B ), implicating the FGF-2/FGF-receptor pathway in the phosphorylation of Sp1. Consistent with these findings, p-Sp1 (Thr453) expression was significantly reduced in TRAIL Ϫ/Ϫ injured arteries ( Figure 6C ). VSMCs transfected with CMV-Sp1 double mutant (CMV-Sp1.mThr453/mThr739) exposed to FGF-2 or injured for 24 hours revealed that FGF-2/injury could no longer activate TRAIL transcription ( Figure 6D ) and ChIP analysis demonstrated an enrichment of p-Sp1(Thr453) on the TRAIL promoter following injury ( Figure 6E ). These findings suggest that injury and FGF-2 activate Sp1 phosphorylation altering its occupancy at the TRAIL promoter to regulate its expression.
NFB and p-Sp1(Thr453) Cooperate Following Injury to VSMCs
Recent studies implicate the involvement of the transcription factor NFB in TRAIL expression. 21 Indeed, overex- Figure 6 . Sp1 binding to the TRAIL promoter is phosphorylated. A, Western blotting for p-Sp1(Thr453) with or without VSMC mechanical scraping injury. Sp1 demonstrates unbiased loading. The intensity of p-Sp1(Thr453) expression relative to Sp1 was determined by densitometry. B, Western blotting for p-Sp1(Thr453) with or without 10 mol/L SU5042 (Calbiochem) an FGF receptor antagonist. Total Sp1 and ␤-actin demonstrate unbiased loading. The intensity of p-Sp1(Thr453) expression relative to Sp1 was determined by densitometry. C, Representative sections of p-Sp1(Thr453) of injured femoral arteries from TRAIL Ϫ/Ϫ mice and WT mice (ϫ100). Positive nuclear staining was quantified using ScanScope as described in Methods (nϭ3). D, TRAIL promoter activity showing that mutation in CMV-Sp1 on Thr453 and Thr739 inhibits injury and FGF-2-inducible TRAIL transcriptional activity. CMV-Sp1mThr453/mThr739 and its control (CMV-SKϩ) were cotransfected with pGL-1523Luc 24 hours before injury of cells by mechanical scraping or FGF-2 (50 ng/mL). Twenty-four hours later, cells were harvested, and luciferase activity determined (nϭ3). E, Binding of p-Sp1(Thr453) and p65-NFB was enriched following 24-hour mechanical injury in ChIP analysis (described in Methods) (nϭ3). Results are representative of at least 2 independent determinations. pression of NFB-p65 increased TRAIL promoter activity and mRNA expression in VSMCs (Online Figure III) . NFB-p65 levels also increased in nuclear extracts of injured VSMCs, whereas nuclear ␤-actin 22 levels were relatively unchanged (Online Figure III) . Nuclear NFB was present 4 hours after cuff placement ( Figure 7A ), implicating its activation and nuclear translocation following cuff-induced arterial injury. Although an NFB consensus (R-R-R-C-W-(N) 0-13 -W-G-Y-Y) was not evident in Oligo-1 and Oligo-2, injury-inducible nucleoprotein complexes containing Sp1also supershifted with antibodies directed to NFB-p65 ( Figure 5B) , and binding of NFB to this region was confirmed using recombinant NFB-p65 ( Figure 7B) .
Given that mutations to the Sp1 consensus sites had significant impact on NFB binding ( Figure 7B ), and the same injury-inducible complex in Oligo-1 and Oligo-2 contains both Sp1 and NFB ( Figure 5B ), imply that Sp1 and NFB cooperate. Transient transfection analysis in VSMCs demonstrated that NFB-inducible TRAIL transcriptional activity was blocked by dominant-negative Sp1 ( Figure 7C ). Coimmunoprecipitation analysis revealed that Sp1 and NFB physically interact, and injury stimulated the association of p-Sp1(Thr453) with NFB ( Figure 7D) . Consistent with this, ChIP analysis also demonstrated an enrichment of NFB-p65 on the TRAIL promoter following injury ( Figure 6E ). Taken together, these studies demonstrate that p-Sp1(Thr453) and NFB play a role in injury-inducible TRAIL promoter activity and expression.
Discussion
We demonstrate for the first time, direct evidence that TRAIL signals play an important role in the pathogenesis of neointimal formation and VSMC proliferation in vivo. Specifically we report that mice deficient in TRAIL are protected from intimal hyperplasia in response to vascular injury. Reduced expression of PCNA-and BrdUrd-positive VSMC in TRAIL Ϫ/Ϫ injured arteries and no effect on apoptosis, implicates TRAIL as a positive regulator of VSMC proliferation. This is consistent with our previous studies which established a proproliferative and prosurvival function of TRAIL on VSMCs by its ability to increase VSMC proliferation in vitro via the induction of the potent growth factor receptor, IGF1R in an NFBdependent manner. 10 Our present findings have significant implications for the role of TRAIL in the development of atherosclerosis. For example, inhibition of TRAIL may provide a potent and selective mechanism for reducing VSMC proliferation after injury.
TRAIL was originally identified by sequence homology to FasL and its ability to induce apoptosis. 23 TRAIL is expressed in atherosclerotic lesions in regions undergoing apoptosis 24, 25 and TRAIL-dependent killing of VSMCs has been described in vitro. 6 However, although TRAIL may regulate apoptosis in the vasculature, the widespread expression of TRAIL observed in a variety of normal human tissues and cells without the induction of apoptosis 23 suggests that the cytotoxicity of TRAIL is selective. Interestingly, serum levels of TRAIL are significantly reduced in patients with coronary artery disease and diabetes, 24, 26, 27 implicating a protective role for TRAIL in cardiovascular pathologies. Consistent with this, Secchiero et al recently showed attenuation of atherosclerotic plaques in diabetic ApoE Ϫ/Ϫ mice by systematic administration of recombinant TRAIL 28 where macrophage, but not VSMC death was observed. 28 Furthermore, there was an increase in VSMC content within the lesions. 28 Although the studies above provide suggestive evidence of the physiological role of TRAIL in vivo, to date, a direct role for TRAIL in cardiovascular pathologies and VSMC function has not been established.
In the present study we used an in vivo model of cuff-induced arterial injury. Cuff injury has been reported of the TRAIL promoter. Binding of NFB is diminished by introducing transverse mutations to the Sp1 elements. C, NFB induction of TRAIL promoter activity is blocked by dominant-negative Sp1 (pEBG-Sp1) compared to the control (pEBG-NLS). Each expression plasmid (2 g each) was transfected together with 1 g of pGL-1523Luc for 24 hours in 6-well-titer plate (nϭ3). D, Coimmunoprecipitation studies demonstrating that the p-Sp1(Thr453) interaction with NFB is increased following injury. Total protein (500 g) from VSMCs was immunoprecipitated with total Sp1 and immunoblotted for NFB and p-Sp1(Thr453). Densitometry was used to determine level of expression relative to Sp1. Results are meansϩSE (nϭ3). *PϽ0.05. Results are representative of at least 2 independent determinations. in studies of VSMC proliferation and intimal thickening, and allows the specific assessment of VSMC function after injury to the vessel wall, without endothelial cell denudation and with limited invasion of circulatory cells. 17, 29 Consistent with this, no alteration to the EC lining was observed after cuff injury, suggesting that the VSMC accumulation that we observe is not a direct effect on EC dysfunction. However, we cannot rule out the possibility that changes at the level of gene expression in ECs could part-take indirectly in VSMC proliferation and subsequent neointimal formation. For example, injury to ECs can induce the expression of vascular endothelial growth factor. 30 vascular endothelial growth factor can indirectly stimulate VSMC proliferation through the modulation of FGF-2 and TGF-␤1 released by ECs. 31 No significant CD45-positive cells were observed within the neointima. This is consistent with previous studies examining the contribution of bone marrow to neointimal hyperplasia following perivascular cuff injury. 17, 32 These studies demonstrated very few marker-positive cells in lesions induced by cuff placement. 32 Furthermore, given that there is no change in macrophage expression, plasma lipid levels or markers of systemic inflammation, this suggest that the effects observed in TRAIL Ϫ/Ϫ mice are not likely to be systemic, but rather direct effects on VSMCs. Indeed, we can reverse the protection of intimal hyperplasia in injured arteries of TRAIL Ϫ/Ϫ mice by daily intraperitoneal injection of human recombinant TRAIL.
We show that TRAIL is under the transcriptional control of injury and FGF-2. The promoter region of TRAIL contains several transcription factor sites including GATA, C/EPB, Ap1, Ap3, CF-1, and ISRE (reviewed 3 ). The 5Ј-proximal promoter also contains 2 putative Sp1 recognition elements (Sp1-1 and Sp1-2) that have not been described to bind Sp1 directly. Here, we show that following injury, Sp1 binds these elements in the proximal TRAIL promoter and that basal, as well as inducible transcriptional activity, is mediated by Sp1. Interestingly, a neutralizing antibody to FGF-2 only blocked Sp1 binding to Oligo-1 and not Oligo-2 in injured VSMC by EMSA analysis. This suggests that the effect of FGF-2 on the binding ability of Sp1 on the TRAIL promoter is only dependent on Sp1-1 and that additional mechanisms operate that can alter Sp1's occupancy of the TRAIL promoter following injury. One such mechanism may be the involvement of NFB. NFB expression is induced following injury. Importantly, NFB overexpression in VSMCs increased TRAIL mRNA and promoter activity. As NFB binds the same Sp1 elements, this suggests that NFB/Sp1 physically interact, further confirmed by our immunoprecipitation and dominant-negative experiments where the structural integrity of Sp1 is critical for the cooperative activation of the TRAIL promoter by these factors.
Sp1 phosphorylation is an important process controlling the expression of many genes including FasL. 19, 33 p42/p44 mitogen-activated protein kinase directly phosphorylates Sp1 on Thr453 and Thr739, 20, 34 and in this study, mutation of residues Thr453 and Thr739 in Sp1 inhibited injury-and FGF-2-inducible TRAIL promoter activity. Consistent with this, p-Sp1(Thr453) was induced after mechanical injury in VSMCs and we showed enrichment of p-Sp1(Thr453) and NFB at the TRAIL promoter ( Figure  8 ). To our knowledge, our study provides the first mechanistic insight into the transcriptional regulation of TRAIL in VSMCs and subsequent VSMC proliferation and intimal hyperplasia in vivo (Figure 8 ). We find both that FGF-2 regulates TRAIL and that FGF-2 itself is regulated by TRAIL, implicating crosstalk between the 2 proteins. FGF-2, released within minutes following vascular injury (Online Figure IV) , 14 is an important regulator of VSMC proliferation 14 and the development of intimal hyperplasia. 13 These findings suggest a positive feedback mechanism which may be associated with acceleration of VSMC proliferation and increased intimal hyperplasia. Thus, our findings advance our present understanding of the complex The acute local release of FGF-2 is stimulated within 2 minutes of injury. FGF-2 binds its receptor, initiating phosphorylation of Sp1 at Thr453 and Thr739. p-Sp1(Thr453) physically interacts with NFB and binds to Sp1-1 and Sp1-2 elements on the TRAIL promoter. Binding of these factors to the promoter increases TRAIL transcriptional activity, mRNA and protein expression. TRAIL not only promotes VSMC proliferation and intimal hyperplasia, but also regulates FGF-2 itself, implicating crosstalk between these 2 proteins. This suggests a positive feedback mechanism that may be associated with acceleration of VSMC proliferation and increased neointima formation. signaling of TRAIL in vascular biology and imply that Sp1 phosphorylation in cooperation with NFB plays an important role in the regulation of TRAIL following injury and FGF-2 treatment.
Novelty and Significance
What Is Known?
• TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) can rapidly induce apoptosis in many transformed cells and is therefore considered a potential therapeutic target in the treatment of cancer. • Recent studies suggest nonapoptotic functions of TRAIL and TRAIL signaling is far more complicated than originally described. • The role and regulation of TRAIL in vivo, in atherosclerosis, and in vascular injury remain undefined.
What New Information Does This Article Contribute?
• Contrary to the widely held view that TRAIL only causes cell death, our study provides the first direct in vivo demonstration of the ability of TRAIL to promote vascular smooth muscle cell (VSMC) proliferation and neointima formation following arterial injury in TRAIL-deficient mice. • We show, for the first time, that regulation of TRAIL expression in VSMCs, in response to injury, involves the potent growth factor FGF-2. • We also provide new mechanistic insights into the transcriptional regulation of TRAIL in arterial injury, ie, FGF-2-inducible TRAIL transcriptional regulation involves transcription factors Sp1 and nuclear factor B.
TRAIL was first discovered as an inducer of apoptosis and subsequently thought to regulate cell death in the vessel wall. More recently, studies have demonstrated nonapoptotic functions of TRAIL in vascular cells, eg, as an inducer of proliferation and migration of VSMCs and endothelial cells. Given the conflicting data (eg, whether it induces apoptosis, proliferation, or both), the role of TRAIL in atherosclerosis and cardiovascular disease is not clear. Here, we provide, for the first time, direct evidence that TRAIL plays an important role in neointimal formation and VSMC proliferation in vivo. Specifically, we show that TRAIL Ϫ/Ϫ mice are protected from intimal thickening and display reduced VSMC proliferation in response to vascular injury. In fact, we can reverse this effect by the systematic administration of TRAIL. Furthermore, we report that TRAIL expression is induced following vascular injury, and involves the growth factor FGF-2, phosphorylation of the transcription factor Sp1, and its interaction with nuclear factor B. Our findings have significant implications in atherosclerosis, eg, inhibition of TRAIL may provide a potent and selective mechanism for reducing VSMC proliferation after injury. Understanding TRAIL regulation may lead to novel approaches in the prevention and/or treatment of complications associated with atherosclerosis and cardiovascular disease.
